Premium
Human primary bone sarcomas contain CD133 + cancer stem cells displaying high tumorigenicity in vivo
Author(s) -
Tirino Virginia,
Desiderio Vincenzo,
Paino Francesca,
De Rosa Alfredo,
Papaccio Federica,
Fazioli Flavio,
Pirozzi Giuseppe,
Papaccio Gianpaolo
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.10-179036
Subject(s) - cd44 , cancer stem cell , sox2 , cd90 , homeobox protein nanog , cd34 , cancer research , cd117 , stem cell , osteosarcoma , biology , stem cell marker , pathology , population , cancer , medicine , cell , induced pluripotent stem cell , embryonic stem cell , microbiology and biotechnology , gene , genetics , environmental health , biochemistry
This study aimed to identify, isolate, and characterize cancer stem cells from human primary sarcomas. We performed cytometric analyses for stemness and differentiation antigens, including CD29, CD34, CD44, CD90, CD117, and CD133, on 21 human primary sarcomas on the day of surgery. From sarcoma biopsies, we obtained 2 chondrosarcoma‐stabilized cell lines and 2 osteosarcoma stabilized cell lines, on which sphere formation, side population profile, stemness gene expression, and in vivo and in vitro assays were performed. All samples expressed the CD133, CD44, and CD29 markers. Therefore, we selected a CD133 + subpopulation from stabilized cell lines that displayed the capacity to grow as sarcospheres able to initiate and sustain tumor growth in nonobese diabetic/severe combined (NOD/SCID) mice, to express stemness genes, including OCT3/4, Nanog, Sox2, and Nestin, and to differentiate into mesenchymal lineages, such as osteoblasts and adipocytes. Our findings show the existence of cancer stem cells in human primary bone sarcomas and highlight CD133 as a pivotal marker for identification of these cells. This may be of primary importance in the development of new therapeutic strategies and new prognostic procedures against these highly aggressive and metastatic tumors.—Tirino, V., Desiderio, V., Paino, F., De Rosa, A, Papaccio, F., Fazioli, F., Pirozzi, G., Papaccio, G. Human primary bone sarcomas contain CD133 + cancer stem cells displaying high tumorigenicity in vivo. FASEB J. 25, 2022‐2030 (2011). www.fasebj.org